Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 4/20 | 0.36 |
| ▸ | TDO2 | P48775 | 3/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7655571 | 1.00 | GRM5 (0.45) | GRM5CYP2D6CHRNB2ADRA2CCHRNB4 | |
| SCHEMBL5662057 | 1.00 | GRM5 (0.45) | GRM5CYP2D6CHRNB2ADRA2CCHRNB4 | |
| SCHEMBL14587411 | 1.00 | GRM5 (0.45) | GRM5CYP2D6CHRNB2ADRA2CCHRNB4 | |
| SCHEMBL14587413 | 1.00 | GRM5 (0.45) | GRM5CYP2D6CHRNB2ADRA2CCHRNB4 | |
| SCHEMBL10242113 | 0.77 | GRM5 (0.54) | GRM5PGRKCNH2 | |
| SCHEMBL7654253 | 0.77 | GRM5 (0.54) | GRM5PGRKCNH2 | |
| SCHEMBL7655582 | 0.77 | GRM5 (0.54) | GRM5PGRKCNH2 | |
| SCHEMBL7654264 | 0.77 | GRM5 (0.54) | GRM5PGRKCNH2 | |
| SCHEMBL6965438 | 0.77 | GRM5 (0.43) | GRM5CHRNB2ADRA2CCHRNB4CHRNA3 | |
| SCHEMBL6964387 | 0.77 | GRM5 (0.46) | GRM5CYP2D6CHRNB2ADRA2CCHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
| US-6372911-B1 | REACTING COMPOUND CONTAINING AT LEAST ONE CARBON-CARBON DOUBLE BOND WITH CARBAMATE IN AQUEOUS SOLVENT IN PRESENCE OF BASE, OSMIUM CATALYST, CO-OXIDANT, AND OPTIONALLY ASYMMETRIC LIGAND, TO FORM REACTION MIXTURE CONTAINING BETA-HYDROXY CARBAMATE | MERCK & CO., INC. | 2002-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | GRM5 609/4885CYP2D6 885/4885CHRNB2 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.